Ricardo Perdigão Henriques, Phd

Headquartered in Portugal’s main biotech park, Biocant, Mondego Bio is developing best-in-class protein tyrosine phosphatase non-receptor type 2 (PTPN2) inhibitors, providing a potential immuno-oncological therapy with an improved safety and tolerability profile.

AccelBio is a collaborative laboratory that aims to be the bridge that brings biomedical science closer to the market. With a set of partners that cover all the necessary capacities and expertise to drive drug discovery. AccelBio selects fundamental research discoveries and cutting-edge technology platforms and tools and guides the transformation of breakthrough science into validated and investment-worthy assets. AccelBio bridges academic research groups and start-ups with industry-standard drug discovery capabilities - target validation, assay development, high-throughput screening, in silico modelling, medicinal chemistry, in vitro and in vivo testing, IP support and business development. Innovative platforms are also being developed within a well-defined R&I agenda that will further boost drug discovery. By providing these capacities and specialized expertise, AccelBio will de-risk drug discovery assets until they are ready to be out-licensed to industry or established as the foundation of new spin-off companies.

Headquartered in Seville, Spain, Vaxdyn works with an international network of collaborators in the development of multi-pathogen vaccines for preventing antibiotics-resistant infections in all regions of the world. Our vaccines target high-risk populations, population affected by chronic diseases of the lungs, liver, kidney, immunocompromised by co-morbidities like diabetes or cancer, populations associated with nursing homes and hospital settings, women affected by recurrent urinary-tract infections, or neonates. We are strongly committed to contribute to reducing antibiotic use in the world by following a One-Health approach. Vaxdyn is the first Spanish biotech funded by CARB-X. CARB-X awarded Vaxdyn in 2020 up to US$1.01 million, plus an additional $6.36 million if certain project milestones are met, to develop KapaVax until completion of the first proof of principle in humans (Phase 1). KapaVax is our first multi-valent candidate designed to raise immunity against Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter baumannii, the top-3 superbacteria of urgent risk of the list of the World Health Organization (WHO).

CellmAbs is focused on researching and developing novel anti-cancer treatments

Chronic wounds affect ~100m people around the world, impacting quality of life & placing a huge burden on health systems. Despite the many innovations in wound care over the years, chronic wound healing rates have barely improved. Change is needed – patients, practitioners, and regulators across the industry are in urgent need of high-impact innovations in chronic wound care. SolasCure is at the forefront of addressing this demand, aiming to shift the current treatment paradigm with a high impact therapeutic approach to debridement, with the goal of enabling dramatic improvements in healing rates and patients’ quality of life. Aurase Wound Gel aims to address the huge unmet need for easy & effective debridement to return wounds to healing. It combines the enzyme Tarumase with hydrogel to debride wounds, reduce biofilm & promote healing. Tarumase is a highly-specific fibrinolytic enzyme cloned from maggot saliva, perfectly optimised by evolution for wound bed preparation. After successful Phase IIa trials, SolasCure is preparing for the next phase of clinical development to bring Aurase Wound Gel one step closer to improving the lives of millions of patients suffering from chronic wounds. For more information, you can find our peer-reviewed publications here: Clinical: https://onlinelibrary.wiley.com/doi/10.1111/iwj.14805 Preclinical: https://onlinelibrary.wiley.com/doi/10.1111/iwj.14079 The importance of our innovative technology has been widely recognised: - Innovate UK Global Incubator Programme (Innovate UK, the UK’s Innovation Agency), Texas Medical Center, 2024 - Biomedical Catalyst Grant (Innovate UK, the UK’s Innovation Agency), 2024 - EIC Accelerator Grant (European Innovation Council), 2023 - Life Sciences Innovator (UK Department for Trade and Business), 2023 - EIT Health Catapult, Biotech Category (European Institute of Innovation & Technology), 2022 - Winner 2019 URGO Mentorship Programme. Visit us at www.solascure.com

Delox is a spin-off of the Faculty of Sciences of the University of Lisbon (FCUL), whose goals consist in the design of a vast portfolio of compact automatic bio-decontamination equipment. Target applications include laboratory equipment bio-decontamination, hospital rooms, as well as delivering bio-decontamination in biodefense, disaster relief and space sectors.

Adapttech is a biomedical innovation company committed to bringing new smart technologies to the O&P market. We aim to empower clinicians with data-driven solutions and patient remote monitoring methods to improve the quality of life of lower-limb prosthetic users.

Anybrain.gg is an AI start-up that provides security and anti-fraud solutions to the gaming industry to secure online gaming and to make esports fairer.

Chronic wounds affect ~100m people around the world, impacting quality of life & placing a huge burden on health systems. Despite the many innovations in wound care over the years, chronic wound healing rates have barely improved. Change is needed – patients, practitioners, and regulators across the industry are in urgent need of high-impact innovations in chronic wound care. SolasCure is at the forefront of addressing this demand, aiming to shift the current treatment paradigm with a high impact therapeutic approach to debridement, with the goal of enabling dramatic improvements in healing rates and patients’ quality of life. Aurase Wound Gel aims to address the huge unmet need for easy & effective debridement to return wounds to healing. It combines the enzyme Tarumase with hydrogel to debride wounds, reduce biofilm & promote healing. Tarumase is a highly-specific fibrinolytic enzyme cloned from maggot saliva, perfectly optimised by evolution for wound bed preparation. After successful Phase IIa trials, SolasCure is preparing for the next phase of clinical development to bring Aurase Wound Gel one step closer to improving the lives of millions of patients suffering from chronic wounds. For more information, you can find our peer-reviewed publications here: Clinical: https://onlinelibrary.wiley.com/doi/10.1111/iwj.14805 Preclinical: https://onlinelibrary.wiley.com/doi/10.1111/iwj.14079 The importance of our innovative technology has been widely recognised: - Innovate UK Global Incubator Programme (Innovate UK, the UK’s Innovation Agency), Texas Medical Center, 2024 - Biomedical Catalyst Grant (Innovate UK, the UK’s Innovation Agency), 2024 - EIC Accelerator Grant (European Innovation Council), 2023 - Life Sciences Innovator (UK Department for Trade and Business), 2023 - EIT Health Catapult, Biotech Category (European Institute of Innovation & Technology), 2022 - Winner 2019 URGO Mentorship Programme. Visit us at www.solascure.com

CellmAbs is focused on researching and developing novel anti-cancer treatments

Delox is a spin-off of the Faculty of Sciences of the University of Lisbon (FCUL), whose goals consist in the design of a vast portfolio of compact automatic bio-decontamination equipment. Target applications include laboratory equipment bio-decontamination, hospital rooms, as well as delivering bio-decontamination in biodefense, disaster relief and space sectors.

Adapttech is a biomedical innovation company committed to bringing new smart technologies to the O&P market. We aim to empower clinicians with data-driven solutions and patient remote monitoring methods to improve the quality of life of lower-limb prosthetic users.

Anybrain.gg is an AI start-up that provides security and anti-fraud solutions to the gaming industry to secure online gaming and to make esports fairer.

We are a Contract Development and Manufacturing Organisation (CDMO) focused on regenerative medicine. Our company addresses product/process development and current Good Manufacturing Practice (cGMP) production and clinical translation of impactful medicinal products. Stemmatters´ core expertise addresses multiple investigational medicinal products (IMPs), including advanced therapy medicinal products (ATMPs), biologicals, and diverse raw materials supporting the product life cycle of innovative therapeutic products.

Headquartered in Portugal’s main biotech park, Biocant, Mondego Bio is developing best-in-class protein tyrosine phosphatase non-receptor type 2 (PTPN2) inhibitors, providing a potential immuno-oncological therapy with an improved safety and tolerability profile.

AccelBio is a collaborative laboratory that aims to be the bridge that brings biomedical science closer to the market. With a set of partners that cover all the necessary capacities and expertise to drive drug discovery. AccelBio selects fundamental research discoveries and cutting-edge technology platforms and tools and guides the transformation of breakthrough science into validated and investment-worthy assets. AccelBio bridges academic research groups and start-ups with industry-standard drug discovery capabilities - target validation, assay development, high-throughput screening, in silico modelling, medicinal chemistry, in vitro and in vivo testing, IP support and business development. Innovative platforms are also being developed within a well-defined R&I agenda that will further boost drug discovery. By providing these capacities and specialized expertise, AccelBio will de-risk drug discovery assets until they are ready to be out-licensed to industry or established as the foundation of new spin-off companies.

Biovance Capital is a biotech-focused venture capital company, investing in early-stage companies across Europe.

Headquartered in Seville, Spain, Vaxdyn works with an international network of collaborators in the development of multi-pathogen vaccines for preventing antibiotics-resistant infections in all regions of the world. Our vaccines target high-risk populations, population affected by chronic diseases of the lungs, liver, kidney, immunocompromised by co-morbidities like diabetes or cancer, populations associated with nursing homes and hospital settings, women affected by recurrent urinary-tract infections, or neonates. We are strongly committed to contribute to reducing antibiotic use in the world by following a One-Health approach. Vaxdyn is the first Spanish biotech funded by CARB-X. CARB-X awarded Vaxdyn in 2020 up to US$1.01 million, plus an additional $6.36 million if certain project milestones are met, to develop KapaVax until completion of the first proof of principle in humans (Phase 1). KapaVax is our first multi-valent candidate designed to raise immunity against Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter baumannii, the top-3 superbacteria of urgent risk of the list of the World Health Organization (WHO).

CellmAbs is focused on researching and developing novel anti-cancer treatments